Ankylosing Spondylitis

Featured Article
Biologic Strategies for Ankylosing Spondylitis Not Cost-Effective at Common Threshold
No biologic strategies in treatment guidelines for ankylosing spondylitis were cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year.
Switching or Discontinuing Ankylosing Spondylitis Biologics Raises Medical Costs
Patients with ankylosing spondylitis who switch or discontinue their biologic within a year of starting it have higher health care utilization and medical costs compared with patients who stay with…
Understanding the Link Between bDMARD Initiation, Switching With Mood Disorders
Researchers found a positive association between the use of antidepressant and anxiolytic medication with both the introduction and switching of bDMARDs.

Newsfeed

Biologic Strategies for Ankylosing Spondylitis Not Cost-Effective at Common Threshold
Switching or Discontinuing Ankylosing Spondylitis Biologics Raises Medical Costs
Understanding the Link Between bDMARD Initiation, Switching With Mood Disorders
Disease Activity in Axial Spondylarthritis Patients Linked With Current State of Health Care Stress
Ankylosing Spondylitis Improvement Sustained After 5 Years of Secukinumab Treatment
Switching SC-TNFi Associated With Higher Nontreatment HCRU Costs
Chronic Opioid Use in Ankylosing Spondylitis Is Concerning
Statins tied to lower mortality risk in ankylosing spondylitis
View More
Back to Top